Verastem Inc. (VSTM)
Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
Verastem Oncology's stock dropped significantly after the announcement of data from the RAMP-205 study investigating avutometinib in combination with standard chemotherapy for metastatic pancreatic cancer. The study showed promising early efficacy signal with 87% response rate, but also a high rate of serious adverse events. Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk.
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Verastem opened 70% down on Friday: what happened?
Verastem Inc (NASDAQ: VSTM) opened nearly 70% down this morning even though the pharmaceutical firm reported positive interim data for its combination therapy as a treatment of pancreatic cancer. Here's what is hitting $VSTM today The oncology company commenced a regulatory submission aimed at U.S. approval for avutometinib and defactinib as well on Friday.
Why Is Verastem (VSTM) Stock Down 62% Today?
Verastem (NASDAQ: VSTM ) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment. The company is conducting a Phase 1/2 clinical trial of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel.
Verastem shares surge more than 50% after pancreatic-cancer treatment study data
Shares of Verastem VSTM, +2.53% rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.
